Edwards Lifesciences Corporation (NYSE:EW) – SunTrust Banks raised their Q2 2018 earnings per share estimates for Edwards Lifesciences Corporation in a research report issued on Monday. SunTrust Banks analyst B. Nudell now forecasts that the medical research company will post earnings of $1.09 per share for the quarter, up from their previous estimate of $0.99. SunTrust Banks has a “Buy” rating and a $14.00 price objective on the stock. SunTrust Banks also issued estimates for Edwards Lifesciences Corporation’s Q3 2018 earnings at $0.94 EPS and FY2021 earnings at $5.89 EPS.

A number of other research analysts have also recently issued reports on the stock. Vetr cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating and set a $124.67 target price for the company. in a report on Monday, May 15th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $125.00 target price for the company in a report on Monday, May 22nd. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Edwards Lifesciences Corporation in a report on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 target price for the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $150.00 target price on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Finally, Jefferies Group LLC set a $115.00 target price on shares of Edwards Lifesciences Corporation and gave the company a “buy” rating in a report on Saturday, May 27th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $121.13.

COPYRIGHT VIOLATION WARNING: This piece was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://theolympiareport.com/2017/08/12/suntrust-banks-weighs-in-on-edwards-lifesciences-corporations-q2-2018-earnings-nyseew-updated.html.

Edwards Lifesciences Corporation (EW) traded down 1.323% during midday trading on Wednesday, reaching $113.745. The company had a trading volume of 776,223 shares. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.75. The firm’s 50 day moving average is $117.23 and its 200 day moving average is $104.41. The stock has a market capitalization of $23.94 billion, a PE ratio of 34.500 and a beta of 0.63.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company had revenue of $842 million for the quarter, compared to analysts’ expectations of $839.16 million. During the same period in the previous year, the firm posted $0.76 EPS. Edwards Lifesciences Corporation’s revenue was up 10.9% compared to the same quarter last year.

Several institutional investors have recently made changes to their positions in the stock. South Texas Money Management Ltd. raised its position in shares of Edwards Lifesciences Corporation by 157.9% in the first quarter. South Texas Money Management Ltd. now owns 344,816 shares of the medical research company’s stock worth $32,437,000 after buying an additional 211,119 shares during the period. Financial Counselors Inc. raised its position in shares of Edwards Lifesciences Corporation by 2.1% in the first quarter. Financial Counselors Inc. now owns 13,637 shares of the medical research company’s stock worth $1,283,000 after buying an additional 282 shares during the period. American Century Companies Inc. raised its position in shares of Edwards Lifesciences Corporation by 7.2% in the first quarter. American Century Companies Inc. now owns 2,046,875 shares of the medical research company’s stock worth $192,550,000 after buying an additional 137,934 shares during the period. Advisor Partners LLC raised its position in shares of Edwards Lifesciences Corporation by 7.5% in the first quarter. Advisor Partners LLC now owns 4,895 shares of the medical research company’s stock worth $460,000 after buying an additional 341 shares during the period. Finally, Torch Wealth Management LLC bought a new position in shares of Edwards Lifesciences Corporation during the first quarter worth $1,635,000. Institutional investors own 83.80% of the company’s stock.

In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 34,120 shares of Edwards Lifesciences Corporation stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $109.98, for a total value of $3,752,517.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $118.05, for a total transaction of $3,883,845.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 178,732 shares of company stock worth $20,320,171. 2.13% of the stock is owned by company insiders.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Earnings History and Estimates for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.